Medidata Solutions Reports Record First Quarter 2013 Results
Medidata Solutions Reports Record First Quarter 2013 Results
Record revenues of $63.3 million, a 26% year-over-year increase
Record application services revenue of $50.7 million, a 32% year-over-year increase
Raises 2013 revenue guidance to between $270 and $274 million
NEW YORK--(BUSINESS WIRE)-- Medidata Solutions (NAS: MDSO) , the leading global provider of cloud-based solutions for the life sciences industry, today announced its financial results for the first quarter 2013 and provided detailed financial guidance.
"With Medidata's customers increasingly relying on our Clinical Cloud platform, we had an impressive first quarter, and have set the foundation for strong performance in the remainder of 2013," said Tarek Sherif, Medidata's chief executive officer. "Our revenue growth is accelerating, our backlog is showing meaningful growth and our customer and revenue retention rates are impressive, all of which are indicative of the attractiveness of our platform and business model. Life science companies are rapidly moving to the cloud and away from the legacy, on-premise solutions offered by our competitors. We expect to continue to be the primary beneficiary of this transition, building value for our customers and shareholders."
First Quarter 2013 Results
Total revenues for the first quarter of 2013 were $63.3 million, an increase of $12.9 million, or 26%, compared with $50.4 million in 2012. Application services revenue was $50.7 million, an increase of 32% compared with the same period last year.
GAAP operating income for the quarter increased to $7.1 million, up 16%, compared with $6.1 million a year ago. Non-GAAP operating income* for the first quarter of 2013 increased to $14.2 million, up 37%, compared with $10.3 million a year ago.
GAAP net income for the first quarter of 2013 was $5.7 million, or $0.22 per diluted share, up 51%, compared with $3.8 million, or $0.15 per diluted share, in the first quarter of 2012. Adjusted non-GAAP net income* for the first quarter of 2013 was $9.1 million, or $0.35 per diluted share, up 69%, compared with $5.4 million, or $0.22 per diluted share, in the first quarter of 2012.
Application services backlog for the remainder of the year (remaining backlog) as of March 31, 2013, increased to $156 million, up 46% over the comparable period a year ago. This compares with a 34% increase in remaining backlog over the comparable period in the prior year. Non-Rave products account for 22% of remaining backlog.
Total cash, cash equivalents and marketable securities were $124.0 million at the end of the first quarter, an increase of $12.8 million as compared with $111.2 million at the end of the first quarter 2012.
Additional Highlights
Medidata's customer base grew to 358 in the first quarter of 2013, up 25% from the first quarter of 2012.
41% of customers had committed to multiple products at the end of the first quarter of 2013 as compared with 38% at the end of the fourth quarter of 2012.
Non-Rave revenues increased 125% year-over-year, driven by healthy growth in Medidata's patient randomization, medical coding, safety data capture, protocol design, business analytics and trial management solutions.
Medidata's revenue retention rate for the quarter was 99.9%.
"Our investments are intended to enhance long-term growth and we are seeing positive signs of their impact in our results," said Cory Douglas, chief financial officer. "We are confident in our ability to drive sustained growth in 2013 and in the years to come."
Financial Outlook
For the full year 2013, the company now expects:
Revenues between $270.0 and $274.0 million.
Professional services revenues in the high $40 million range.
Non-GAAP operating income between $61.0 and $64.0 million. Based on current estimates, this would equate to GAAP operating income between $23.0 and $26.0 million.
Adjusted non-GAAP net income, which includes the tax affected impact primarily from stock-based compensation and amortization at a 40% effective tax rate, between $31.5 and $34.5 million. Based on current estimates, this would equate to GAAP net income between $13.5 and $16.5 million.
While changes in the stock price could change the fully diluted share count, the company is assuming 26.7 million fully diluted shares.
For the second quarter of 2013, the company expects:
Revenues between $65.5 and $67.0 million.
Non-GAAP operating income between $14.0 and $15.0 million. Based on current estimates, this would equate to GAAP operating income between $3.5 and $4.5 million.
Adjusted non-GAAP net income, which includes the tax affected impact primarily from stock-based compensation and amortization at a 40% effective tax rate, between $7.0 and $8.0 million. Based on current estimates, this would equate to GAAP net income between $1.5 and $2.5 million.
While changes in the stock price could change the fully diluted share count, the company is assuming 26.7 million fully diluted shares.
Conference Call
The company plans to host its investor conference call today at 8:00 a.m. Eastern. The investor conference call will be available via live webcast on the "Investor" section of Medidata's web site at http://investor.mdsol.com. To participate by telephone, domestic participants may dial 877-303-2528 and international participants may dial 847-829-0023. Those interested in participating in the conference call should dial in at least 10 minutes prior to the call to register. Participants can also join the call via a simultaneous live audio webcast, which will be made available on the "Investor" section of Medidata's web site at http://investor.mdsol.com. A replay of the conference call can be accessed until Monday, May 13, 2013 by dialing 800-585-8367 domestically or 404-537-3406 internationally, with the passcode 35896019. An archive of the call will also be hosted on the "Investor" section of Medidata's web site, http://investor.mdsol.com, for a limited period of time.
About Medidata Solutions Worldwide
Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.
Cautionary Statement
Certain statements made in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Medidata Solutions, Inc. ("Medidata"), including but not limited to statements about Medidata's forecast of financial performance, products and services, business model, strategy and growth opportunities, and competitive position. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, risks associated with possible fluctuations in our financial and operating results; errors, interruptions or delays in our service or our Web hosting; the financial impact of any future acquisitions; our ability to continue to release, and gain customer acceptance of, new and improved versions of our products; changes in our sales and implementation cycles; competition; our ability to retain and expand our customer base or increase new business from those customers; our ability to hire, retain and motivate our employees and manage our growth; regulatory developments; litigation; and general developments in the economy. For additional disclosure regarding these and other risks faced by the company, see disclosures contained in Medidata's public filings with the Securities and Exchange Commission including, the "Risk Factors" section of Medidata's Annual Report on Form 10-K for the year ended December 31, 2012. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and Medidata undertakes no obligation to update such statements as a result of new information.
*Non-GAAP Financial Information
Medidata provides Non-GAAP operating income, net income and net income per share applicable to common stockholders data as additional information for its operating results. These measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from Non-GAAP measures used by other companies. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, stock-based compensation expense, and an adjustment to the fair value of contingent consideration.Non-GAAP net income excludes the impact of amortization of intangible assets associated with acquisitions, stock-based compensation expense, and an adjustment to the fair value of contingent consideration. Adjusted non-GAAP net income excludes the impact of tax-affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, and an adjustment to the fair value of contingent consideration.Management uses these Non-GAAP measures to evaluate its financial results, develop budgets, manage expenditures, and as an important factor in determining variable compensation. In addition, investors frequently have requested information from management regarding depreciation and amortization and non-cash, share-based compensation charges and management believes, based on discussions with investors, that these Non-GAAP measures enhance investors' ability to assess Medidata's historical and project future financial performance. While management believes these Non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of Non-GAAP financial measures. One limitation of Non-GAAP operating income is that it excludes depreciation and amortization, which represents the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in our business. Medidata compensates for these limitations by using these Non-GAAP financial measures as supplements to GAAP financial measures and by reviewing the reconciliations of the Non-GAAP financial measures to their most comparable GAAP financial measures. Investors are encouraged to review the reconciliations of these Non-GAAP financial measures to the comparable GAAP results, which are attached to this press release.
MEDIDATA SOLUTIONS, INC. | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||
(Amounts in thousands, except per share data) | ||||||||
Three Months Ended March 31, | ||||||||
2013 | 2012 | |||||||
Revenues | ||||||||
Application services | $ | 50,652 | $ | 38,396 | ||||
Professional services | 12,607 | 11,963 | ||||||
Total revenues | 63,259 | 50,359 | ||||||
Cost of revenues (1)(2) | ||||||||
Application services | 9,025 | 7,484 | ||||||
Professional services | 8,104 | 7,131 | ||||||
Total cost of revenues | 17,129 | 14,615 | ||||||
Gross profit | 46,130 | 35,744 | ||||||
Operating costs and expenses: | ||||||||
Research and development(1) | 11,905 | 9,955 | ||||||
Sales and marketing (1)(2) | 14,489 | 10,383 | ||||||
General and administrative (1) | 12,644 | 9,290 | ||||||
Total operating costs and expenses | 39,038 | 29,628 | ||||||
Operating income | 7,092 | 6,116 | ||||||
Interest and other income (expense): | ||||||||
Interest expense | (18 | ) | (21 | ) | ||||
Interest income | 76 | 71 | ||||||
Other income, net | 154 | — | ||||||
Total interest and other income, net | 212 | 50 | ||||||
Income before income taxes | 7,304 | 6,166 | ||||||
Provision for income taxes | 1,604 | 2,396 | ||||||
Net income | $ | 5,700 | $ | 3,770 | ||||
Earnings per share: | ||||||||
Basic | $ | 0.23 | $ | 0.16 | ||||
Diluted | $ | 0.22 | $ | 0.15 | ||||
Weighted average common shares outstanding: | ||||||||
Basic | 25,120 | 24,017 | ||||||
Diluted | 26,261 | 24,842 | ||||||
(1) Stock-based compensation expense included in cost of revenues and operating costs and expenses is as follows: | ||||||||
Cost of revenues | $ | 487 | $ | 295 | ||||
Research and development | 458 | 192 | ||||||
Sales and marketing | 1,222 | 564 | ||||||
General and administrative | 3,038 | 1,103 | ||||||
Total stock-based compensation | $ | 5,205 | $ | 2,154 | ||||
(2) Amortization expense of intangible assets included in costs of revenues and operating costs and expenses is as follows: | ||||||||
Cost of revenues | $ | 281 | $ | 318 | ||||
Sales and marketing | 113 | 129 | ||||||
Total amortization of intangible assets | $ | 394 | $ | 447 | ||||
MEDIDATA SOLUTIONS, INC. | ||||||||
Reconciliation of GAAP Operating Income and GAAP Net Income to Non-GAAP Operating Income, Non-GAAP Net Income, and Adjusted Non-GAAP Net Income (Unaudited) | ||||||||
(Amounts in thousands, except per share data) | ||||||||
Three Months Ended March 31, | ||||||||
2013 | 2012 | |||||||
Operating income: | ||||||||
GAAP operating income | $ | 7,092 | $ | 6,116 | ||||
GAAP operating margins | 11.2 | % | 12.1 | % | ||||
Stock-based compensation | 5,205 | 2,154 | ||||||
Depreciation and amortization | 1,851 | 1,994 | ||||||
Contingent consideration adjustment (1) | 60 | 80 | ||||||
Non-GAAP operating income | $ | 14,208 | $ | 10,344 | ||||
Non-GAAP operating margins | 22.5 | % | 20.5 | % | ||||
Net income: | ||||||||
GAAP net income | $ | 5,700 | $ | 3,770 | ||||
Stock-based compensation | 5,205 | 2,154 | ||||||
Amortization | 394 | 447 | ||||||
Contingent consideration adjustment (1) | 60 | 80 | ||||||
Non-GAAP net income | 11,359 | 6,451 | ||||||
Tax impact on add-back items (2) | (2,264 | ) | (1,072 | ) | ||||
Adjusted non-GAAP net income | $ | 9,095 | $ | 5,379 | ||||
GAAP basic earnings per share | $ | 0.23 | $ | 0.16 | ||||
GAAP diluted earnings per share | $ | 0.22 | $ | 0.15 | ||||
Non-GAAP basic earnings per share | $ | 0.45 | $ | 0.27 | ||||
Non-GAAP diluted earnings per share | $ | 0.43 | $ | 0.26 | ||||
Adjusted Non-GAAP basic earnings per share | $ | 0.36 | $ | 0.22 | ||||
Adjusted Non-GAAP diluted earnings per share | $ | 0.35 | $ | 0.22 | ||||
(1) Amount represents the effect of changes in fair value of contingent consideration liability. | ||||||||
(2) Tax impact calculated using a 40% tax rate. | ||||||||
The table above presents a reconciliation of GAAP to non-GAAP operating income, net income, and net income per share applicable to common stockholders for the three months ended March 31, 2013 and 2012. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, stock-based compensation expense, and adjustment to the fair value of contingent consideration. Non-GAAP net income excludes the impact of amortization of intangible assets associated with acquisitions, stock-based compensation expense, and adjustment to the fair value of contingent consideration. Adjusted non-GAAP net income excludes the impact of tax affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, and adjustment to the fair value of contingent consideration.
MEDIDATA SOLUTIONS, INC. | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||||
(Amounts in thousands, except per share data) | ||||||||
March 31, 2013 | December 31, 2012 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 37,291 | $ | 32,683 | ||||
Marketable securities | 83,086 | 89,871 | ||||||
Accounts receivable, net of allowance for doubtful accounts of $1,130 and $747, respectively | 48,398 | 42,359 | ||||||
Prepaid commission expense | 3,113 | 2,281 | ||||||
Prepaid expenses and other current assets | 7,717 | 8,042 | ||||||
Deferred income taxes | 6,731 | 7,465 | ||||||
Total current assets | 186,336 | 182,701 | ||||||
Restricted cash | — | 388 | ||||||
Furniture, fixtures and equipment, net | 10,542 | 10,474 | ||||||
Marketable securities, long-term | 3,655 | — | ||||||
Goodwill | 15,081 | 15,382 | ||||||
Intangible assets, net | 1,230 | 1,708 | ||||||
Deferred income taxes, long-term | 10,752 | 11,055 | ||||||
Other assets | 2,823 | 2,923 | ||||||
Total assets | $ | 230,419 | $ | 224,631 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,319 | $ | 2,998 | ||||
Accrued payroll and other compensation | 7,716 | 14,140 | ||||||
Accrued expenses and other | 7,134 | 6,674 | ||||||
Deferred revenue | 53,213 | 50,348 | ||||||
Capital lease obligations | 55 | 55 | ||||||
Total current liabilities | 69,437 | 74,215 | ||||||
Noncurrent liabilities: | ||||||||
Deferred revenue, less current portion | 3,722 | 4,323 | ||||||
Deferred tax liabilities | 293 | 624 | ||||||
Capital lease obligations, less current portion | 86 | 100 | ||||||
Other long-term liabilities | 2,739 | 3,278 | ||||||
Total noncurrent liabilities | 6,840 | 8,325 | ||||||
Total liabilities | 76,277 | 82,540 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, par value $0.01 per share; 5,000 shares authorized, none issued and outstanding | — | — | ||||||
Common stock, par value $0.01 per share; 100,000 shares authorized, 26,946 and 26,405 shares issued; 26,570 and 26,039 shares outstanding, respectively | 269 | 264 | ||||||
Additional paid-in capital | 168,102 | 160,637 | ||||||
Treasury stock, 376 and 366 shares, respectively | (5,752 | ) | (5,626 | ) | ||||
Accumulated other comprehensive income (loss) | (1,056 | ) | (63 | ) | ||||
Accumulated deficit | (7,421 | ) | (13,121 | ) | ||||
Total stockholders' equity | 154,142 | 142,091 | ||||||
Total liabilities and stockholders' equity | $ | 230,419 | $ | 224,631 | ||||
MEDIDATA SOLUTIONS, INC. | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | ||||||||
(Amounts in thousands) | ||||||||
